Prostate cancer and prostate bed SPECT imaging with ProstaScint®: Semiquantitative correlation with prostatic biopsy results

Sodee, D. Bruce; Ellis, Rodney J.; Samuels, Michael Α.; Spirnak, J. Patrick; Poole, Wayne F.; Riester, Clifford; Martanovic, Dawn M.; Stonecipher, Robert; Bellon, Errol M.

doi:10.1002/(sici)1097-0045(19981101)37:3<140::aid-pros3>3.0.co;2-q

Cited by 49 publications

(27 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, the F(ab ¶) 2 (26,27). Although some extracellular proteases can be imaged using radiolabeled antibodies, such as ProstaScint imaging of the prostate-specific membrane antigen acting as a glutamate carboxypeptidase (28), targeting of proteases is extremely challenging. All currently known successful trapping mechanisms of small molecules addressing proteases use suicide inhibition and, thus, are not recommended for nuclear imaging.…”

Section: Probes and Probe Developmentmentioning

confidence: 99%

Nuclear Imaging Probes: from Bench to Bedside

Wester

2007

Clinical Cancer Research

103

View full text Add to dashboard Cite

The availability of specific imaging probes is the nuclear fuel for molecular imaging by positron emission tomography and single-photon emission computed tomography. These two radiotracer-based imaging modalities represent the prototype methods for noninvasive depiction and quantification of biochemical processes, allowing a functional characterization of tumor biology. A variety of powerful radiolabeled probesötracersöare already established in the routine clinical management of human disease and others are currently subject to clinical assessment. Emerging from investigations of the genomic and proteomic signatures of cancer cells, an increasing number of promising targets are being identified, including receptors, enzymes, transporters, and antigens. Corresponding probes for these newly identified targets need to be developed and transferred into the clinical setting. Starting with a brief summary of the characteristics and prerequisites for a ''good tracer,'' an overview of tracer concepts, target selection, and development strategies is given. The influence of the imaging concepts on tracer development is also discussed.

show abstract

Section: Probes and Probe Developmentmentioning

confidence: 99%

Nuclear Imaging Probes: from Bench to Bedside

Wester

2007

Clinical Cancer Research

103

View full text Add to dashboard Cite

show abstract

“…We further hypothesized that pelvic SPECT/CT image sets could simultaneously provide a systematic method of image-guided radiation therapy dose escalation (IGRT-DE) to areas of higher tumor burden in the prostate gland (7)(8)(9). In the present study, we describe the 10-year actuarial longitudinal outcomes in our prospective treatment cohort.…”

Section: Introductionmentioning

confidence: 99%

Ten-Year Outcomes: The Clinical Utility of Single Photon Emission Computed Tomography/Computed Tomography Capromab Pendetide (Prostascint) in a Cohort Diagnosed With Localized Prostate Cancer

Ellis

Kaminsky

Zhou

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

“…We have previously reported the feasibility of single photon emission computed tomography and computed tomography image fusion (SPECT/CT) ProstaScint for identification of intraprostatic foci of disease with histopathologic confirmation (18,19). We have also previously presented subgroup analysis reporting 4-year actuarial biochemical disease-free survival (bDFS) outcomes using our SPECT/CT BTV dose escalation protocol (20e22).…”

Section: Introductionmentioning

confidence: 99%